Howard A Burris

Summary

Publications

  1. ncbi request reprint Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Howard A Burris
    The Sarah Cannon Research Institute, 250 25th Avenue N, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 23:5305-13. 2005
  2. ncbi request reprint Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    David R Spigel
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA
    J Thorac Oncol 2:854-61. 2007
  3. doi request reprint Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
    Howard A Burris
    Drug Development Program, Sarah Cannon Research Institute, Nashville, Tennessee, USA
    Cancer 119:1908-15. 2013
  4. doi request reprint Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
    Howard A Burris
    Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA
    Cancer Chemother Pharmacol 71:829-42. 2013
  5. doi request reprint Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors
    Howard A Burris
    Sarah Cannon Research Institute, 250 25th Ave North, Suite 110, Nashville, TN 37203, USA
    Mol Cancer Ther 11:1820-8. 2012
  6. doi request reprint Preclinical investigations with epothilones in breast cancer models
    Howard A Burris
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Semin Oncol 35:S15-21; quiz S39. 2008
  7. pmc A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies
    Howard A Burris
    The Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Clin Cancer Res 15:6702-8. 2009
  8. doi request reprint Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
    Howard A Burris
    Drug Development, Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203 1632, USA
    Expert Opin Biol Ther 11:807-19. 2011
  9. doi request reprint Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
    Howard A Burris
    Sarah Cannon Research Institute, Nashville, TN 37203 1632, USA
    J Clin Oncol 29:398-405. 2011
  10. doi request reprint Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs
    H A Burris
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Oncogene 28:S4-13. 2009

Detail Information

Publications90

  1. ncbi request reprint Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Howard A Burris
    The Sarah Cannon Research Institute, 250 25th Avenue N, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 23:5305-13. 2005
    ....
  2. ncbi request reprint Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    David R Spigel
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA
    J Thorac Oncol 2:854-61. 2007
    ..Imatinib targets KIT expression, providing rationale for studying its role in combination with chemotherapy in SCLC in a multicenter phase II trial...
  3. doi request reprint Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
    Howard A Burris
    Drug Development Program, Sarah Cannon Research Institute, Nashville, Tennessee, USA
    Cancer 119:1908-15. 2013
    ..This analysis investigated the treatment effects on health-related quality of life (HRQOL)...
  4. doi request reprint Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
    Howard A Burris
    Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA
    Cancer Chemother Pharmacol 71:829-42. 2013
    ..Novel strategies to overcome resistance by targeting these signaling pathways are being evaluated...
  5. doi request reprint Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors
    Howard A Burris
    Sarah Cannon Research Institute, 250 25th Ave North, Suite 110, Nashville, TN 37203, USA
    Mol Cancer Ther 11:1820-8. 2012
    ..Given the antitumor activity of this regimen, further studies are underway to determine a clinically tolerable schedule of pazopanib with paclitaxel and carboplatin...
  6. doi request reprint Preclinical investigations with epothilones in breast cancer models
    Howard A Burris
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Semin Oncol 35:S15-21; quiz S39. 2008
    ....
  7. pmc A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies
    Howard A Burris
    The Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Clin Cancer Res 15:6702-8. 2009
    ..This study determined the range of tolerable doses, clinical safety, pharmacokinetics, and preliminary evidence of clinical activity following once or twice daily administration of lapatinib in patients with solid malignancies...
  8. doi request reprint Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
    Howard A Burris
    Drug Development, Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203 1632, USA
    Expert Opin Biol Ther 11:807-19. 2011
    ..Effective therapies are limited in HER2-positive advanced or metastatic breast cancer (MBC), particularly following progression on available HER2-targeted therapies...
  9. doi request reprint Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
    Howard A Burris
    Sarah Cannon Research Institute, Nashville, TN 37203 1632, USA
    J Clin Oncol 29:398-405. 2011
    ....
  10. doi request reprint Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs
    H A Burris
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Oncogene 28:S4-13. 2009
    ..This review discusses the limitations of currently recommended therapies for patients with advanced NSCLC and discusses new agents in clinical development for this disease...
  11. doi request reprint Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma
    Howard A Burris
    Sarah Cannon Research Institute, Nashville, Tenessee 37203 1632, USA
    Clin Cancer Res 16:1673-81. 2010
    ..RAAG12 is highly expressed on many adenocarcinomas, particularly those of gastrointestinal origin. A phase 1 dose-escalation safety and pharmacokinetics trial was conducted in patients with metastatic or recurrent adenocarcinomas...
  12. pmc Radiation recall with anticancer agents
    Howard A Burris
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Oncologist 15:1227-37. 2010
    ....
  13. doi request reprint A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine
    Jeffrey R Infante
    Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA
    Cancer Chemother Pharmacol 69:137-44. 2012
    ..To address tolerability and a possible pharmacologic interaction of capecitabine with sorafenib...
  14. doi request reprint Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction
    David R Spigel
    Sarah Cannon Research Institute, 3322 West End Ave, Suite 201, Nashville, TN 37203, USA
    J Clin Oncol 28:2213-9. 2010
    ..This multicenter community-based phase I/II trial examined a modern triplet regimen comprised of oxaliplatin, docetaxel, and capecitabine (ODC) combined with radiation therapy (RT)...
  15. doi request reprint Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, 250 25th Ave North, Ste 110, Nashville, TN 37203, USA
    J Clin Oncol 29:2582-9. 2011
    ..Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non-small-cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or without sorafenib in this multicenter phase II trial...
  16. ncbi request reprint Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network
    F Anthony Greco
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, USA
    Clin Lung Cancer 8:483-7. 2007
    ....
  17. doi request reprint Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Colorectal Cancer 11:45-52. 2012
    ..We wanted to evaluate the efficacy, defined as 2-year disease-free survival (DFS), and safety of bevacizumab/chemoradiation in preoperative and adjuvant settings for patients with stage II/III rectal cancer...
  18. doi request reprint A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 7:196-202. 2012
    ..To assess time to progression (TTP) in elderly patients with previously untreated nonsquamous non-small cell lung cancer treated with pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab...
  19. ncbi request reprint Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Adv Hematol Oncol 8:480-5, 498. 2010
    ..To examine FOLFOX/bevacizumab/cetuximab in the first-line treatment of metastatic colorectal cancer (mCRC)...
  20. ncbi request reprint Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial
    F Anthony Greco
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, Tennessee 37203, USA
    Oncologist 9:644-52. 2004
    ....
  21. doi request reprint Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Lung Cancer 77:359-64. 2012
    ..This phase II trial was designed to evaluate the role of sunitinib monotherapy following 6 cycles of irinotecan and carboplatin in patients with newly diagnosed extensive-stage (ES) SCLC...
  22. doi request reprint Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 116:2448-54. 2010
    ..In the current study, the combination of oxaliplatin and capecitabine in patients with recurrent and refractory CUP was examined...
  23. ncbi request reprint Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial
    David R Spigel
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Lung Cancer 7:127-32. 2005
    ..Patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients...
  24. doi request reprint Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma
    John D Hainsworth
    Sarah Cannon Research Institute, 3322 West End Ave, Suite 900, Nashville, TN 37203, USA
    J Clin Oncol 28:2131-6. 2010
    ..To evaluate the efficacy and toxicity of the combination of bevacizumab, an angiogenesis inhibitor, and everolimus, an mTOR inhibitor, in the treatment of patients with advanced clear cell renal carcinoma...
  25. doi request reprint Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer
    Jeffrey R Infante
    Tennessee Oncology, PLLC, Nashville, TN, USA
    Clin Breast Cancer 9:23-8. 2009
    ..We investigated the feasibility and safety of a 3-drug combination of trastuzumab, docetaxel, and vinorelbine as first-line therapy in this patient group...
  26. ncbi request reprint Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial
    F Anthony Greco
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Oncologist 10:728-33. 2005
    ..gsk.com) with paclitaxel, carboplatin (Paraplatin; Bristol-Myers Squibb), and etoposide (Etopophos, VePesid; Bristol-Myers Squibb) in patients with previously untreated extensive-stage small cell lung cancer...
  27. ncbi request reprint A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 5:862-6. 2010
    ..In this multicenter, community-based phase II trial, we evaluated carboplatin and weekly topotecan in the previously untreated patients with extensive stage SCLC...
  28. doi request reprint Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:178-83. 2009
    ..We investigated the activity and toxicity of the gemcitabine/trastuzumab combination as first- or second-line treatment in women with HER2+ metastatic breast cancer (MBC)...
  29. pmc Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial
    Jeffrey R Infante
    Sarah Cannon Research Institute, Nashville, TN USA
    Cancer Biol Ther 14:340-6. 2013
    ..To evaluate the 6-mo overall survival, safety and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer...
  30. doi request reprint Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:237-42. 2009
    ..The efficacy of weekly docetaxel is not improved by concurrent administration of imatinib as a PDGFR inhibitor...
  31. doi request reprint A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Breast Cancer 8:425-31. 2008
    ....
  32. doi request reprint Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Lung Cancer 11:198-203. 2010
    ..This multicenter, community-based trial was designed to examine the role of cetuximab in combination with a nonplatinum regimen...
  33. doi request reprint Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 4:1555-60. 2009
    ..Bevacizumab's role in the treatment of small cell lung cancer (SCLC) is unknown. A multicenter phase II trial with bevacizumab plus chemotherapy was conducted in patients with untreated extensive-stage SCLC...
  34. doi request reprint Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee, USA
    Cancer 115:2138-46. 2009
    ..The authors evaluated the feasibility, toxicity, and efficacy of gefitinib added to first-line combined-modality therapy for patients with locally advanced squamous carcinoma of the head and neck...
  35. doi request reprint Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors
    Jeffrey R Infante
    Sarah Cannon Research Institute, 250 25th Avenue North, Suite 200, Nashville, TN 37203, USA
    Invest New Drugs 31:927-36. 2013
    ..We sought to define the maximum tolerated dose (MTD) and evaluate the safety, pharmacokinetics, and preliminary clinical activity of pazopanib plus pemetrexed in patients with solid tumors...
  36. ncbi request reprint A Phase I trial of protracted oral fixed-dose temozolomide
    Suzanne F Jones
    The Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 104:1985-91. 2005
    ..The current Phase I trial was conducted to determine the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended Phase II dose of oral fixed-dose temozolomide when administered for 5 of every 7 days on a continuous basis...
  37. ncbi request reprint A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer
    Suzanne F Jones
    The Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Lung Cancer 6:361-6. 2005
    ....
  38. doi request reprint Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Lung Cancer 78:70-5. 2012
    ..This phase II study examined ixabepilone/carboplatin (cohort A) and ixabepilone/carboplatin/bevacizumab (cohort B) as first-line therapy for patients with advanced NSCLC...
  39. doi request reprint A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors
    Suzanne F Jones
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Cancer Chemother Pharmacol 70:471-5. 2012
    ..To determine the maximum tolerated doses and dose-limiting toxicities of oral panobinostat in combination with paclitaxel and carboplatin when administered to patients with advanced solid tumors...
  40. doi request reprint Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 11:297-305. 2011
    ..We investigated the feasibility and efficacy of bevacizumab in combination with trastuzumab, nab-paclitaxel, and carboplatin as neoadjuvant therapy for women with locally advanced HER2(+) breast cancer...
  41. doi request reprint Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer
    Howard A Burris
    Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN 37203, USA
    Cancer Invest 28:408-12. 2010
    ..These results do not support further investigation of thalidomide for MBC. The role of angiogenesis inhibition in breast cancer treatment should continue to be defined using more efficacious and specific inhibitors...
  42. doi request reprint Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 5:841-5. 2010
    ..Pemetrexed and gemcitabine are safe and active non-small cell lung cancer (NSCLC) therapies when administered every 3 weeks. Biweekly scheduling was studied in this phase II trial...
  43. doi request reprint A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer
    Jeffrey R Infante
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Eur J Cancer 47:199-205. 2011
    ..This phase I study was performed to identify the optimal dose of pomalidomide to be used in combination with gemcitabine in the treatment of patients with metastatic pancreatic cancer...
  44. ncbi request reprint A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Adv Hematol Oncol 9:280-6. 2011
    ..To examine the safety of sorafenib combined with standard adjuvant treatment in patients with node-positive or otherwise high-risk breast cancer...
  45. doi request reprint A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:247-52. 2009
    ..We aim to compare the efficacy and toxicity of liposomal doxorubicin and weekly docetaxel as first-line treatments for patients with metastatic breast cancer (MBC)...
  46. doi request reprint A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer
    Suzanne Jones
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Lung Cancer 9:154-9. 2008
    ..This randomized phase II trial evaluated the efficacy and toxicity of oral topotecan compared with intravenous docetaxel in the second-line treatment of patients with non-small-cell lung cancer (NSCLC)...
  47. ncbi request reprint Phase I. Trial of irinotecan and temozolomide in patients with solid tumors
    Suzanne F Jones
    Sarah Cannon Cancer Center, Tennessee Oncology, PLLC Nashville, Tennessee, USA
    Oncology (Williston Park) 17:41-5. 2003
    ..The recommended phase II doses of irinotecan and temozolomide on treatment arms 1 and 3 remain to be determined as patient accrual is currently ongoing...
  48. doi request reprint A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, Tennesee, USA
    Cancer Invest 28:925-31. 2010
    ..The vinflunine/trastuzumab combination was active and well tolerated, but our results do not suggest advantages over taxane/trastuzumab or vinorelbine/trastuzumab...
  49. ncbi request reprint Phase II trial of vinflunine in relapsed small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 5:874-8. 2010
    ..Vinflunine is a new microtubule inhibitor with preclinical activity in small cell lung cancer (SCLC). In this phase II trial, we evaluated vinflunine in patients with relapse-sensitive and refractory SCLC...
  50. doi request reprint A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 10:367-72. 2010
    ..Patients and..
  51. ncbi request reprint A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors
    Suzanne F Jones
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Adv Hematol Oncol 9:225-30. 2011
    ..To evaluate the safety and tolerability of the combination of orally administered panobinostat with gemcitabine in patients with advanced solid tumors...
  52. ncbi request reprint A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer
    Johanna C Bendell
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Clin Adv Hematol Oncol 10:430-7. 2012
    ..The primary endpoint was the pathologic complete response (pCR) rate...
  53. doi request reprint Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 11:146-52. 2011
    ..This phase II trial evaluated the feasibility and efficacy of bevacizumab added to either anastrozole or fulvestrant in the first-line treatment of patients who have hormone receptor-positive metastatic breast cancer...
  54. ncbi request reprint Phase I. Trial of irinotecan plus carboplatin in two dose schedules
    Suzanne F Jones
    Sarah Cannon Cancer Center, Tennessee Oncology, PLLC Nashville, Tennessee, USA
    Oncology (Williston Park) 17:36-40. 2003
    ..With this amended regimen, the recommended phase II doses are irinotecan at 90 mg/m2 in combination with carboplatin at AUC 2.0 on days 1 and 8, with treatment cycles repeated every 21 days...
  55. doi request reprint Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors
    Suzanne F Jones
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Cancer Invest 30:481-6. 2012
    ..Results suggest additive hematologic toxicities of romidepsin plus gemcitabine, but the level of antitumor activity observed warrants more formal trials of this combination to further assess safety and efficacy...
  56. pmc A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies
    Howard A Burris
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Oncologist 15:954-60. 2010
    ..This phase I study evaluated the safety, tolerability, preliminary antitumor activity, and pharmacokinetic interaction of weekly topotecan (days 1 and 8) in combination with pemetrexed (day 1 only) in patients with advanced solid tumors...
  57. doi request reprint Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab
    David R Spigel
    Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 28:43-8. 2010
    ..Strategies to safely incorporate novel antiangiogenic agents into combined-modality therapy in lung cancer are needed...
  58. doi request reprint Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Cancer 116:4122-9. 2010
    ....
  59. ncbi request reprint Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Cancer J 8:311-21. 2002
    ..The purpose of this study was to evaluate the feasibility, toxicity, and efficacy of a novel combined-modality treatment for patients with locally advanced squamous carcinoma of the head and neck...
  60. ncbi request reprint A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies
    Suzanne F Jones
    Drug Development Program, Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Clin Adv Hematol Oncol 9:845-52. 2011
    ..This phase I study was conducted to determine the dose-limiting toxicity, maximum-tolerated doses, and recommended phase II doses of the combination of vatalanib and bevacizumab...
  61. doi request reprint Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer
    Jeffrey R Infante
    Sarah Cannon Research Institute Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Eur J Cancer 49:1169-75. 2013
    ....
  62. doi request reprint Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Genitourin Cancer 5:427-32. 2007
    ....
  63. ncbi request reprint Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    Cancer Invest 21:193-9. 2003
    ..However, novel treatment approaches are necessary before substantial improvements in treating this patient population will be realized...
  64. doi request reprint A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Cancer Invest 29:451-5. 2011
    ..To evaluate the activity of panobinostat in refractory renal carcinoma...
  65. doi request reprint Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors
    Jeffrey R Infante
    Sarah Cannon Research Institute, Nashville, TN, USA
    J Clin Oncol 30:1527-33. 2012
    ..The objectives of this study were to identify the recommended phase II dose (RP2D) and assess safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-00562271...
  66. ncbi request reprint Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    The Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Cancer 94:2426-33. 2002
    ....
  67. ncbi request reprint Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited Liability Corporation, Nashville, TN, USA
    J Clin Oncol 20:4261-7. 2002
    ....
  68. ncbi request reprint Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer
    Howard A Burris
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer Invest 120:408-12. 2010
    ..These results do not support further investigation of thalidomide for MBC. The role of angiogenesis inhibition in breast cancer treatment should continue to be defined using more efficacious and specific inhibitors...
  69. doi request reprint A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Breast Cancer 8:242-8. 2008
    ..Because docetaxel might be more active than paclitaxel in the treatment of metastatic breast cancer, we explored the feasibility of substituting docetaxel for paclitaxel in dose-dense adjuvant therapy...
  70. doi request reprint Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium
    John D Hainsworth
    Sarah Cannon Research Institute Nashville, Tennessee 37203, USA
    Cancer Invest 28:275-9. 2010
    ..Treatment was well tolerated, with myelosuppression as the only frequent toxicity. Vinflunine has a low level of activity in the treatment of refractory metastatic prostate cancer, and should not be further developed for this indication...
  71. doi request reprint Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Lymphoma Myeloma Leuk 10:44-50. 2010
    ..In this phase II trial, we treated this group of patients with a novel regimen containing 3 courses of rituximab/chemotherapy followed by maintenance rituximab...
  72. doi request reprint A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
    Howard A Burris
    The Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    Invest New Drugs 29:467-72. 2011
    ....
  73. doi request reprint A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN, USA
    Clin Lung Cancer 12:187-91. 2011
    ..V.) weekly dosing resulted in low-grade 3/4 toxicity but an overall response rate (ORR) < 10%. We hypothesized that higher topotecan dosing could improve ORR without significantly increasing toxicity...
  74. doi request reprint Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
    Johanna C Bendell
    Sarah Cannon Research Institute, Nashville, TN, USA
    J Clin Oncol 30:282-90. 2012
    ..This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), safety, preliminary activity, pharmacokinetics (PK), and pharmacodynamics of BKM120, a potent and highly specific oral pan-Class I PI3K inhibitor...
  75. ncbi request reprint Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib
    Howard A Burris
    Sarah Cannon Cancer Center and Tennessee Oncology, Nashville, Tennessee 37203, USA
    Oncologist 9:10-5. 2004
    ..Lapatinib currently is being evaluated in phase II and phase III trials in patients with metastatic breast cancer...
  76. ncbi request reprint Recent updates on the role of chemotherapy in pancreatic cancer
    Howard A Burris
    The Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, USA
    Semin Oncol 32:S1-3. 2005
    ..Promising results in a phase II trial of gemcitabine in combination with bevacizumab have led to a randomized comparative trial of the combination. Potential combinations with other biologic agents are being investigated...
  77. ncbi request reprint Phase II trial of oral rubitecan in previously treated pancreatic cancer patients
    Howard A Burris
    III, The Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, Tennessee 37203, USA
    Oncologist 10:183-90. 2005
    ..This phase II, open-label trial was developed to assess the safety and efficacy of rubitecan in patients with locally advanced or metastatic pancreatic cancer refractory to conventional chemotherapy...
  78. ncbi request reprint Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study
    F Anthony Greco
    Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited Liability Corporation, Centennial Medical Center, Nashville, TN 37203, USA
    J Clin Oncol 20:1651-6. 2002
    ..To evaluate the efficacy and toxicity of the novel chemotherapy combination that includes gemcitabine, carboplatin, and paclitaxel in the treatment of patients with carcinoma of unknown primary site...
  79. doi request reprint Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations
    Howard A Burris
    The Sarah Cannon Research Institute, 3322 West End Ave, Nashville, TN 37203, USA
    Cancer Chemother Pharmacol 67:1045-54. 2011
    ..This crossover phase 1 study compared the pharmacokinetics and safety of tanespimycin, an HSP90 inhibitor, when administered as a suspension for injection and tanespimycin injection, a Cremophor-based formulation...
  80. ncbi request reprint Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
    Howard A Burris
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Semin Oncol 33:S3-16; quiz S41-2. 2006
    ..Continued investigation of LMWH therapy in patients with cancer is warranted...
  81. ncbi request reprint Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies
    Suzanne Jones
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville 37203, USA
    Invest New Drugs 20:55-61. 2002
    ..Higher doses of JM-216 are associated with more severe thrombocytopenia and delayed hematologic recovery resulting in subsequent dosing delays...
  82. doi request reprint Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer
    Anna Maria Storniolo
    Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Dr, Room 473, Indianapolis, IN 46202, USA
    J Clin Oncol 26:3317-23. 2008
    ..This phase I study assessed the safety, clinical feasibility, optimally tolerated regimen (OTR), pharmacokinetics (PK), and preliminary clinical activity of this combination in patients with ErbB2-positive advanced breast cancer...
  83. doi request reprint Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
    ANNE O'DONNELL
    Royal Marsden Hospital, Sutton, Surrey, UK
    J Clin Oncol 26:1588-95. 2008
    ..To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001)...
  84. ncbi request reprint Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial
    F Anthony Greco
    The Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville 37203, USA
    Cancer 95:1279-85. 2002
    ..The authors compared the toxicity, response rate, and progression free survival of four chemotherapy regimens for patients with advanced (Stage IIIB and IV) nonsmall cell lung carcinoma...
  85. ncbi request reprint A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies
    Suzanne F Jones
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville 37203, USA
    Oncologist 7:444-50. 2002
    ..This phase I study was conducted to determine the dose-limiting toxicity (DLT), maximum-tolerated doses, and recommended phase II doses of the combination of weekly intravenous paclitaxel and oral eniluracil/5-fluorouracil (5-FU)...
  86. ncbi request reprint Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer
    Eva Thomas
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 25:3399-406. 2007
    ..This international phase II trial assessed the activity of ixabepilone in patients with metastatic breast cancer (MBC) that was resistant to taxane therapy...
  87. ncbi request reprint Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Carol Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:1082-8. 2007
    ..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated...
  88. ncbi request reprint Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
    Shirin Khambata-Ford
    Bristol Myers Squibb Co, Princeton, NJ 08543, USA
    J Clin Oncol 25:3230-7. 2007
    ..This study was conducted to identify markers that are associated with disease control in patients treated with cetuximab...
  89. doi request reprint Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    J Clin Oncol 26:3051-6. 2008
    ..This phase I study assessed the safety, optimally tolerated regimen (OTR), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of lapatinib and docetaxel in patients with advanced solid tumors...
  90. ncbi request reprint Does intraosseous equal intravenous? A pharmacokinetic study
    Daniel D Von Hoff
    Translational Genomics Research Institute and Arizona Cancer Center, University of Arizona, Phoenix, AZ 85721, USA
    Am J Emerg Med 26:31-8. 2008
    ..The objective of the study was to compare the pharmacokinetics of intraosseous vs intravenous administration of morphine sulfate in adults...